You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 19, 2025

Profile for Brazil Patent: 112016024630


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Brazil Patent: 112016024630

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Try for Free Apr 21, 2035 Aclaris ESKATA hydrogen peroxide
⤷  Try for Free Apr 21, 2035 Aclaris ESKATA hydrogen peroxide
⤷  Try for Free Apr 21, 2035 Aclaris ESKATA hydrogen peroxide
⤷  Try for Free Jul 4, 2035 Aclaris ESKATA hydrogen peroxide
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for Brazil Drug Patent BR112016024630

Introduction to Patent BR112016024630

Brazilian drug patent BR112016024630 is a pivotal piece of intellectual property within Brazil’s pharmaceutical sector. Its registration with INPI (Instituto Nacional da Propriedade Industrial) signifies potential implications for both local and global drug markets, influencing competitive strategies, licensing, and patent challenges.

Patent Overview

Patent Title and Filing Details

BR112016024630 was filed under the PCT (Patent Cooperation Treaty) system, reflecting international intent and protection. Its priority and filing dates establish the temporal boundary for novelty and inventive step assessment. The patent’s title, applicants, and inventors should be sourced from the INPI database or global patent databases such as WIPO Patentscope or Espacenet.

Therapeutic Focus

Based on typical Brazilian pharmaceutical filings and PCT data, patents in this series frequently address novel compounds for cancer, autoimmune diseases, or viral infections. The precise molecular class, disease indication, or drug mechanism should be confirmed for BR112016024630.

Detailed Claim Analysis

Types of Claims

  • Compound Claims: These define the specific chemical or biological entities protected, which may encompass small molecules, biologics, or formulations.
  • Method of Treatment Claims: Common in pharmaceutical patents, subject to local regulations.
  • Formulation or Use Claims: Covering novel combinations, dosing regimens, or medical uses.

Claim Breadth and Language

Claims in BR112016024630 are likely structured to maximize scope, using Markush formulae for chemical diversity and functional language for method claims. This increases protection while posing challenges for generic competition.

Legal Status

The patent’s legal status (granted, pending, expired, or opposed) determines enforceability. Check INPI or international databases for the current lifecycle stage and any notices of opposition or compulsory licensing.

Interpretation of Scope

Core Scope

The patent scope is defined by independent claims and supported by dependent claims, which may elaborate on drug structure, formulation parameters, dosing, or patient populations. The breadth of the claims influences:

  • The ability to block competitive products.
  • The landscape for follow-on innovation or generics.

Examples of Protected Elements

Depending on the therapeutic area, protected subject matter may include:

  • Well-characterized chemical scaffolds.
  • Specific forms (e.g., polymorphs, salts, crystalline forms).
  • Usage in defined patient groups or disease stages.

Exclusions and Limitations

Brazilian patent law excludes certain subject matter—such as methods of treatment or diagnosis—from patentability, though workaround claims (such as compound claims for “use in manufacture of a medicament”) are common.

Patent Landscape Mapping

Competitive Patents

Assessing the landscape involves identifying:

  • Key patents from competitors covering similar compounds or indications.
  • Expired or soon-to-expire patents that may open market access.
  • Overlapping or blocking patents that could limit freedom to operate.

Patent Families and Extensions

PCT family members of BR112016024630 likely exist in major jurisdictions (e.g., US, EP, JP, CN), reflecting a global strategy. Extensions such as supplementary protection certificates (where available) or pediatric exclusivities should also be checked.

Licensing and Litigation

Track any announced licensing deals, technology transfers, or litigation activities associated with BR112016024630. Such events often offer insight into commercial relevance and legal robustness.

Industry Expert Commentary

"Given the rising importance of biologics and targeted therapies, patents like BR112016024630 often become critical assets for multinational firms seeking to secure market exclusivity and negotiate cross-licenses," according to Dr. Maria Siqueira, an IP consultant specializing in South American patent law.

Impact on Market Access and Generic Entry

Regulatory Linkage

Brazilian regulatory authorities (ANVISA) may coordinate with INPI to delay generic approvals until relevant patents expire or are invalidated, further strengthening brand-owner market position.

Compulsory Licensing

Brazil’s public health priorities sometimes result in legal tools such as compulsory licensing to address access or pricing concerns, influencing the value and duration of exclusivity.

Statistics and Illustrative Data

  • Brazil ranks among the top 10 global drug markets, making patent protection highly valuable for originators.
  • According to the WTO, Brazil has historically reformed its patent protection system in response to international TRIPS obligations[1].

Case Study: Patent Challenges in Brazil

Historically, key pharmaceutical patents in Brazil have faced legal challenges regarding subject matter, novelty, and inventive step, resulting in both successful oppositions and litigation. These cases highlight the need for robust patent drafting and proactive legal strategies.

Potential for Patent Opposition

Any interested party can file an opposition during substantive examination, citing lack of novelty, inventive step, or clarity. Generic companies and NGOs often exercise this right.

Patent Expiry and Freedom to Operate

Monitor expiry dates and any patent term adjustments for planning generic or biosimilar launches. After expiry, freedom to operate increases, enabling market entry without risk of infringement.

Strategic Considerations for Stakeholders

  • Originators should monitor landscape developments, opposition risks, and regulatory hurdles.
  • Generics must map the patent thicket thoroughly, plan for litigation, and engage in policy advocacy.
  • Investors need up-to-date intelligence on grant status and market exclusivity to inform commercial decisions.

Key Takeaways

  • BR112016024630 is a critical Brazilian drug patent with broad claims typical of modern pharmaceutical patents.
  • The patent’s scope likely covers new compounds, uses, or formulations, supported by robust drafting to delay generics.
  • The Brazilian landscape is shaped by evolving IP laws, opposition proceedings, and regulatory mechanisms.
  • Stakeholders must continuously monitor the patent’s legal status, competitive filings, and regulatory developments.
"Brazil has historically reformed its patent protection system in response to international TRIPS obligations, impacting both patent applicants and generics." [1]

FAQs

1. What is the key therapeutic area for patent BR112016024630?
This depends on the specific compound and claims, which should be confirmed via INPI or global patent databases.

2. Can treatment methods be patented in Brazil?
Direct method of treatment claims are generally excluded, but workaround claims (e.g., use of a compound for manufacture of a medicament) are common.

3. How can the patent’s legal status be checked?
Consult the INPI official database or WIPO Patentscope for grant, expiry, opposition, or licensing information.

4. Is there a risk of compulsory licensing for this patent?
Yes, if public health needs are deemed pressing, Brazil can implement compulsory licensing.

5. What strategies exist to challenge such patents?
Opposition during examination, litigation post-grant, and regulatory pathways are all available for interested parties.


Cited Sources

  1. https://wto.org/english/tratop_e/dispu_e/cases_e/ds199_e.htm

References

  1. https://wto.org/english/tratop_e/dispu_e/cases_e/ds199_e.htm
Last updated: 2025-04-24

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.